Abstract
Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPAs proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.
Keywords: uPAR, diagnosis, prognosis, imaging, targeting, therapy, exosomes, tumor, rheumatoid arthritis, AIDS, ELISA, nano-particles, biopsies, Image-guided surgery (IGS), renal threshold
Current Pharmaceutical Design
Title: Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Volume: 17 Issue: 19
Author(s): Martin C. Boonstra, Hein W. Verspaget, Sjam Ganesh, Frank J.G.M. Kubben, Alexander L. Vahrmeijer, Cornelis J.H. van de Velde, Peter J.K. Kuppen, Paul H.A. Quax and Cornelis F.M. Sier
Affiliation:
Keywords: uPAR, diagnosis, prognosis, imaging, targeting, therapy, exosomes, tumor, rheumatoid arthritis, AIDS, ELISA, nano-particles, biopsies, Image-guided surgery (IGS), renal threshold
Abstract: Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPAs proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.
Export Options
About this article
Cite this article as:
C. Boonstra Martin, W. Verspaget Hein, Ganesh Sjam, J.G.M. Kubben Frank, L. Vahrmeijer Alexander, J.H. van de Velde Cornelis, J.K. Kuppen Peter, H.A. Quax Paul and F.M. Sier Cornelis, Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients, Current Pharmaceutical Design 2011; 17 (19) . https://dx.doi.org/10.2174/138161211796718233
DOI https://dx.doi.org/10.2174/138161211796718233 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Beclin 1 Biology and its Role in Heart Disease
Current Cardiology Reviews The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Cell Contact/Adhesion Proteins Lgl and DFak56: Tumorigenic and Whole-Organism Vital Effects Studied in Drosophila
Anti-Cancer Agents in Medicinal Chemistry Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Chemopreventive and Anti-leukemic Effects of Ethanol Extracts of Moringa oleifera Leaves on Wistar Rats Bearing Benzene Induced Leukemia
Current Pharmaceutical Biotechnology Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging ATP-Binding Cassette Transporters at the Blood-Brain Barrier in Ischaemic Stroke
Current Pharmaceutical Design The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery Control of Mycobacterium tuberculosis Infection by Glutathione
Recent Patents on Anti-Infective Drug Discovery Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets